ArticleScientific reports2026
The MEOX1-PAX1 axis coordinately regulates tumor cell malignancy and Treg differentiation in glioblastoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) remains a significant therapeutic challenge. This study identified the MEOX1-PAX1 axis as a novel signaling pathway that drives tumor malignancy and fosters immunosuppression. Functional analysis in GBM cells revealed that the transcription factor MEOX1 enhances proliferation, migration, and invasion while suppressing apoptosis, with these effects mediated by its repression of the tumor suppressor PAX1. Notably, beyond its intrinsic cellular role, PAX1 expression in GBM cells strongly influences CD4+ T cell differentiation: overexpression of PAX1 inhibited, while its knockdown promoted, the development of immunosuppressive regulatory T cells (Tregs). This study uncovers the MEOX1-PAX1 axis as a key regulator of GBM progression, promoting both tumor aggressiveness and the creation of an immunosuppressive TME by facilitating Treg differentiation. Targeting this axis offers a promising dual-targeted therapeutic approach for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.